Abstract
Glucagon-like peptide-1 (GLP-1) is involved in satiety control and glucose homeostasis. Besides, GLP-1 has cardiovascular effects. In experimental models, GLP-1 increases cardiac output and exerts a direct vasodilatory effect. In animals with dilated cardiomyopathy GLP-1 improves left ventricular performance. Human data demonstrated that GLP-1 reduces arterial blood pressure, improves endothelial function in individuals with diabetes and left ventricular function in patients with heart failure. Administration of GLP-1 increases ejection fraction in acute myocardial infraction and reduces ischemia-reperfusion myocardial injury. Although more research is needed, these data suggest that GLP-1 may be used with promising results in patients with heart failure, acute myocardial infarction and revascularization procedures in addition to the standard therapy.
Keywords: Arterial blood pressure, cardiovascular, endothelium, glucagon-like peptide 1, heart failure, left ventricular function, type 2 diabetes mellitus, GLP-1, T2DM, cell proliferation, insulin resistant and hyperlipidemic, glomerulosclerosis, angiotensin II, Bilateral vagotomy, hyperglycemia, dilated cardiomyopathy, norepinephrine, cediranib, thrombolysis, angioplasty, low-flow ischaemia, flow mediated vasodilatation, LVEF, acetylcholine, acute occlusive ischemia
Mini-Reviews in Medicinal Chemistry
Title: Cardiovascular Effects of Glucagon-Like Peptide 1
Volume: 11 Issue: 1
Author(s): A. Papazafiropoulou, S. I. Pappas, D. Papadogiannis and N. Tentolouris
Affiliation:
Keywords: Arterial blood pressure, cardiovascular, endothelium, glucagon-like peptide 1, heart failure, left ventricular function, type 2 diabetes mellitus, GLP-1, T2DM, cell proliferation, insulin resistant and hyperlipidemic, glomerulosclerosis, angiotensin II, Bilateral vagotomy, hyperglycemia, dilated cardiomyopathy, norepinephrine, cediranib, thrombolysis, angioplasty, low-flow ischaemia, flow mediated vasodilatation, LVEF, acetylcholine, acute occlusive ischemia
Abstract: Glucagon-like peptide-1 (GLP-1) is involved in satiety control and glucose homeostasis. Besides, GLP-1 has cardiovascular effects. In experimental models, GLP-1 increases cardiac output and exerts a direct vasodilatory effect. In animals with dilated cardiomyopathy GLP-1 improves left ventricular performance. Human data demonstrated that GLP-1 reduces arterial blood pressure, improves endothelial function in individuals with diabetes and left ventricular function in patients with heart failure. Administration of GLP-1 increases ejection fraction in acute myocardial infraction and reduces ischemia-reperfusion myocardial injury. Although more research is needed, these data suggest that GLP-1 may be used with promising results in patients with heart failure, acute myocardial infarction and revascularization procedures in addition to the standard therapy.
Export Options
About this article
Cite this article as:
Papazafiropoulou A., I. Pappas S., Papadogiannis D. and Tentolouris N., Cardiovascular Effects of Glucagon-Like Peptide 1, Mini-Reviews in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/138955711793564033
DOI https://dx.doi.org/10.2174/138955711793564033 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery The Application of NMR Spectroscopy for the Study of Heart Failure
Current Pharmaceutical Design Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Beta-Blockers use for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Flavonoids and Chagas' Disease: The Story So Far!
Current Topics in Medicinal Chemistry Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in Experimental Myocarditis
Current Pharmaceutical Design Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design Endothelial Dysfunction in Heart Failure: Mechanisms and Therapeutic Approaches
Current Vascular Pharmacology The C-Reactive Protein Levels in Left Ventricular Dysfunction of Different Etiology
Inflammation & Allergy - Drug Targets (Discontinued) Antidotal Effects of Curcumin Against Agents-Induced Cardiovascular Toxicity
Cardiovascular & Hematological Disorders-Drug Targets Drugs Targeting the Canonical NF-κB Pathway to Treat Viral and Autoimmune Myocarditis
Current Pharmaceutical Design Synergistic Effect of Inhibitors of MMPs and ROS-dependent Modifications of Contractile Proteins on Protection Hearts Subjected to Oxidative Stress
Current Pharmaceutical Design Pleiotropic Effects of Simvastatin on Some Calcium Regulatory and Myofibrillar Proteins in Ischemic/Reperfused Heart: Causality of Statins Cardioprotection?
Current Pharmaceutical Design Pharmacological Regulators of Intracellular Calcium Release Channels
Current Pharmaceutical Design Peripartum Cardiomyopathy: An Intriguing Challenge. Case Report with Literature Review
Current Cardiology Reviews The Role of Molecular Imaging in the Assessment of Cardiac Amyloidosis: State-of-the-Art
Current Radiopharmaceuticals Mitophagy and Disease: New Avenues for Pharmacological Intervention
Current Pharmaceutical Design Natriuretic Peptide Family: New Aspects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Toll-Like Receptors and Myocardial Ischemia/Reperfusion, Inflammation, and Injury
Current Cardiology Reviews